Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study
Endocrine · 2023
DOI: 10.1007/s12020-022-03230-5 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrine, 2023. Verfasst von Aliya A Khan und 16 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Ontario, Canada. aliya@mcmaster.ca. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Osteoporosis, Fractures, Bone. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We evaluated the effect of low dose denosumab (30 mg every 6 months) on the prevention of bone loss following a switch from standard dose (60 mg of denosumab every 6 months) in a prospective observational study.
Methods
We recruited 114 women 50–90 years of age with postmenopausal osteoporosis at a moderate fracture risk without prior fragility fractures, who had been on denosumab 60 mg every 6 month. These women switched to low dose denosumab 30 mg every 6 months. Mean percentage change in lumbar spine (LS), femoral neck (FN), total hip (TH) and 1/3 distal radius (1/3RAD) BMD at 12 and 24 months were evaluated. Predictors for change in BMD were explored. Subgroup analysis for patients on denosumab 60 mg every 6 months for
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McMaster University, Hamilton, Ontario, Canada. aliya@mcmaster.ca.
- McMaster University, Hamilton, Ontario, Canada.
- Bone Research and Education Centre, Oakville, Ontario, Canada.
ORCID-Profile: Aliya A Khan
Zitieren
APA
Khan, A. A., AbuAlrob, H., M'Hiri, I., Ali, D. S., Dandurand, K., Said, H., Alkassem, H., Hakami, Y., Hweija, I., Iqbal, S., Romanovschi, M., Mehmood, S., Zariffeh, H., Guyatt, G., Ibrahim, Q., Brignardello-Petersen, R., & Syed, H. I. (2023). Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine. https://doi.org/10.1007/s12020-022-03230-5
Vancouver
Khan AA, AbuAlrob H, M'Hiri I, Ali DS, Dandurand K, Said H, et al. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine. 2023. doi:10.1007/s12020-022-03230-5
BibTeX
@article{Khan2023,
author = {Khan, Aliya A and AbuAlrob, Hajar and M'Hiri, Iman and Ali, Dalal S and Dandurand, Karel and Said, Hosay and Alkassem, Hisham and Hakami, Yasser and Hweija, Ismail and Iqbal, Salman and Romanovschi, Mihai and Mehmood, Shehryar and Zariffeh, Heather and Guyatt, Gordon and Ibrahim, Quazi and Brignardello-Petersen, Romina and Syed, Hamza I},
title = {Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study},
journal = {Endocrine},
year = {2023},
doi = {10.1007/s12020-022-03230-5}
}
EUVIMED